Global human insulin drug market is estimated to be valued at USD 52.47 Bn in 2024, and is expected to exhibit a CAGR of 8.5% during the forecast period (2024-2031). Global human insulin drug market has been witnessing steady growth over the past few years, owing to increasing prevalence of diabetes across the world. Human insulin drugs are biosynthetically manufactured versions of regular human insulin that is used for the treatment and management of diabetes. According to the data published by the International Diabetes Federation, approximately 463 million adults lived with diabetes in 2019 and the number is expected to rise to 700 million by 2045. Growing diabetic population, rising awareness about insulin therapy, introduction of innovative insulin drug delivery systems such as insulin pens and pumps are expected to boost demand for human insulin drugs globally.
Market Dynamics:
Global human insulin drug market growth is primarily driven by growing incidence of diabetes owing to obesity, sedentary lifestyle, aging population, and genetic factors. According to WHO, diabetes is one of the major causes of death with an estimated 1.5 million deaths caused by diabetes every year. Rising awareness about insulin therapy and various innovative drug delivery options for insulin administration such as insulin pumps and pens can drive the market growth. However, high cost of human insulin drugs can hamper the market growth. The development of biosimilar human insulin drugs provides lucrative growth opportunities for players in the market.
Key Features of the Study:
Detailed Segmentation-
Table of Contents
*Browse 34 market data tables and 28 figures on "Human Insulin Drug Market” - Global forecast to 2031
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients